Medtronic concludes enrollment in 'extreme risk' study of CoreValve

Medtronic ($MDT) has wrapped up patient enrollment in the extreme risk study in its CoreValve U.S. Pivotal Trial. The study is enrolling more than 1,500 patients in 45 sites, with approximately two-thirds of patients in the high-risk study. The system is designed to replace diseased aortic valves without open-heart surgery. Medtronic release

Suggested Articles

Medtronic has moved to acquire Avenu Medical, developers of a minimally invasive method of building the blood vessel access ports.

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.